Human epidermal growth factor receptor 2 testing: Where are we?

Journal of Clinical Oncology

Volumn 28, Issue 28, 2010, Pages 4289-4292

  De, Pradip ^a   Smith, Brian R ^b   Leyland Jones, Brian ^a  

^a EMORY UNIVERSITY   (United States)

^b VM Institute of Research   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; TRASTUZUMAB; ANTINEOPLASTIC AGENT; DNA; HER2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TUMOR MARKER;

BREAST CANCER; CANCER CHEMOTHERAPY; CHROMOSOME 17; CLINICAL TRIAL (TOPIC); DRUG DETERMINATION; DRUG SCREENING; EDITORIAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE IDENTIFICATION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; BREAST TUMOR; CANCER INVASION; FEMALE; GENETICS; METABOLISM; NOTE; ONCOLOGY; PRACTICE GUIDELINE; STANDARD;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DNA, NEOPLASM; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MEDICAL ONCOLOGY; NEOPLASM INVASIVENESS; PRACTICE GUIDELINES AS TOPIC; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 78049437579     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.29.5071     Document Type: Editorial

References (49)

1. Baehner FL, Achacoso N, Maddala T, et al: Human epidermal growth factor receptor 2 assessment in a case-control study: Comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories. J Clin Oncol 28:4300-4306, 2010
2. Vogelstein B, Kinzler KW: The Genetic Basis of Human Cancer. New York, NY, McGraw Hill, 1998, pp xv-xix
3. Scaltriti M, Verma C, Guzman M, et al: Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 28:803-814, 2009
4. Staaf J, Ringné r M, Vallon-Christersson J, et al: Identification of subtypes in human epidermal growth factor receptor 2-positive breast cancer reveals a gene signature prognostic of outcome. J Clin Oncol 28:1813-1820, 2010
5. Akiyama T, Sudo C, Ogawara H, et al: The product of the human c-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity. Science 232:1644-1646, 1986 (Pubitemid 16095607)
6. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/Neu oncogene. Science 235:177-182, 1987 (Pubitemid 17231334)
7. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809-820, 2006 (Pubitemid 43290919)
8. Perez EA, Suman VJ, Davidson NE, et al: HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 24:3032-3038, 2006 (Pubitemid 46638937)
9. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005 (Pubitemid 41464706)
10. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145, 2007 (Pubitemid 350003059)
11. Roche PC, Suman VJ, Jenkins RB, et al: Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 94:855-857, 2002 (Pubitemid 34705058)
12. Newcomer LN: The Responsibility to pay for cancer treatments: A health insurer's view of value. Oncologist 15:32-35, 2010 (suppl 1)
13. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001 (Pubitemid 32222155)
14. Bast RC Jr, Ravdin P, Hayes DF, et al: 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1865-1878, 2001
15. Pauletti G, Dandekar S, Rong H, et al: Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 18:3651-3664, 2000
16. Press MF, Sauter G, Bernstein L, et al: Diagnostic evaluation of HER-2 as a molecular target: An assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 11:6598-6607, 2005 (Pubitemid 41339000)
17. Mass RD, Sanders C, Charlene K, et al: The concordance between the Clinical Trials Assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin Pivotal Trials. Proc Am Soc Clin Oncol 19:75a, 2000 (abstr 291)
18. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131:18-43, 2007 (Pubitemid 46174133)
19. Hammond ME, Hayes DF, Dowsett M, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784-2795, 2010
20. Dowsett M, Bartlett J, Ellis IO, et al: Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol 199:418-423, 2003 (Pubitemid 36411217)
21. Gancberg D, Lespagnard L, Rouas G, et al: Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas: Correlation with oncogene amplification in 160 cases. Am J Clin Pathol 113:675-682, 2000 (Pubitemid 33044308)
22. Perez EA, Roche PC, Jenkins RB, et al: HER2 testing in patients with breast cancer: Poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc 77:148-154, 2002 (Pubitemid 34118890)
23. Ma Y, Lespagnard L, Durbecq V, et al: Polysomy 17 in HER-2/neu status elaboration in breast cancer: Effect on daily practice. Clin Cancer Res 11:4393-4399, 2005 (Pubitemid 40825629)
24. Paik S, Bryant J, Tan-Chiu E, et al: Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 94:852-854, 2002 (Pubitemid 34705057)
25. Anderson S, Reddy JC, Rai S, et al: Concordance between central and local lab IHC and FISH HER2 testing in a community-based trial of first-line trastuzumab plus a taxane in HER2+. J Clin Oncol 23:851, 2004 (suppl; abstr 9580)
26. Viale G: Pathological definition of triple negative breast cancer. Presented at 2009 ECCO-ESMO: The joint Congress of the European Cancer Organisation and Congress of the European Society for Medical Oncology Meeting, Berlin, Germany, September 21-24, 2009
27. O'Leary TJ: Standardization in immunohistochemistry. Appl Immunohistochem Mol Morphol 9:3-8, 2001
28. Reiner-Concin A, Regitnig P, Dinges HP, et al: Practice of HER-2 immunohistochemistry in breast carcinoma in Austria. Pathol Oncol Res 14:253-259, 2008
29. Dowsett M, Procter M, McCaskill-Stevens W, et al: Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: The HERA Trial. J Clin Oncol 27:2962-2969, 2009
30. Paik S, Kim C, Wolmark N: HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 358:1409-1411, 2008 (Pubitemid 351468442)
31. Arnould L, Arveux P, Couturier J, et al: Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification. Clin Cancer Res 13:6404-6409, 2007 (Pubitemid 350075030)
32. Khoury T, Sait S, Hwang H, et al: Delay to formalin fixation effect on breast biomarkers. Mod Pathol 22:1457-1467, 2009
33. Hofmann MK, Gross C, Beyser K, et al: Predictive value of HercepTest IHC and PathVysion FISH data: Analysis from a trastazumab phase II monotherapy study. Proc Am Soc Clin Oncol 22:185, 2003 (abstr 740)
34. Perez EA, Romond EH, Suman VJ, et al: Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HERs-positive breast cancer. J Clin Oncol 25:6s, 2007 (abstr 512)
35. Kaufman PA, Broadwater G, Lezon-Geyda K, et al: CALGB 150002: Correlation of HER2 and chromosome 17 (ch17) copy number with trastuzumab (T) efficacy in CALGB 9840, paclitaxel (P) with or without T in HER2+ and HER2- metastatic breast cancer (MBC). J Clin Oncol 25:34s, 2007 (abstr 1009)
36. Downey L, Livingston RB, Koehler M, et al: Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer. Clin Cancer Res 16:1281-1288, 2010
37. Dandachi N, Dietze O, Hauser-Kronberger C: Evaluation of the clinical significance of HER2 amplification by chromogenic in situ hybridisation in patients with primary breast cancer. Anticancer Res 24:2401-2406, 2004 (Pubitemid 39166323)
38. Peiró G, Mayr D, Hillemanns P, et al: Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization, HER-2/neu, p53 and Ki-67 protein expression, and outcome. Mod Pathol 17:227-287, 2004
39. Todorović-Raković N, Jovanović D, Nesković-Konstantinović Z, et al: Prognostic value of HER2 gene amplification detected by chromogenic in situ hybridization (CISH) in metastatic breast cancer. Exp Mol Pathol 82:262-268, 2007 (Pubitemid 46691311)
40. Yeh IT, Martin MA, Robetorye RS, et al: Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event. Mod Pathol 22:1169-1175, 2009
41. Lambros MB, Natrajan R, Reis-Filho JS: Chromogenic and fluorescent in situ hybridization in breast cancer. Hum Pathol 38:1105-1122, 2007 (Pubitemid 47058171)
42. Genomic Health: Oncotype DX. http://www.genomichealth.com/OncotypeDX/ Index.aspx
43. Ross JS: Multigene predictors in early-stage breast cancer: Moving in or moving out? Expert Rev Mol Diagn 8:129-135, 2008
44. Yaziji H, Goldstein LC, Barry TS, et al: HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 291:1972-1977, 2004
45. Kulka J, Tôkés AM, Kaposi-Novák P, et al: Detection of HER-2/neu gene amplification in breast carcinomas using quantitative real-time PCR: a comparison with immunohistochemical and FISH results. Pathol Oncol Res 12:197-204, 2006
46. Susini T, Bussani C, Marini G, et al: Preoperative assessment of HER-2/neu status in breast carcinoma: The role of quantitative real-time PCR on core-biopsy specimens. Gynecol Oncol 116:234-239, 2010
47. Vinatzer U, Dampier B, Streubel B, et al: Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: Quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization. Clin Cancer Res 11:8348-8357, 2005 (Pubitemid 41746947)
48. Roepman P, Horlings HM, Krijgsman O, et al: Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer. Clin Cancer Res 15:7003-7011, 2009
49. Pusztai L, Ayers M, Stec J, et al: Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res 9:2406-2415, 2003 (Pubitemid 36842079)